On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion.
Operational growth was 6.7%, and adjusted operational growth was 5.7%.
Innovative Medicine sales increased to $14.33 billion, up 4.4% (+6.1% adjusted operational).
Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains and market growth. Overall cancer sales increased to $5.49 billion.
Also Read: FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
Growth was partially offset by Stelara (ustekinumab). Stelara sales fell 14.7% to $2.35 billion. Darzalex sales rose 20.9% to $3.08 billion. The company's cancer cell therapy, Carvykti, generated sales of $334 million.
MedTech sales increased 6.7% to 8.19 billion, driven by global procedure growth, new product performance, and the Shockwave deal. Growth was partially offset by endocutter products in Advanced Surgery.
Guidance: Johnson & Johnson expects 2025 sales of $90.9 billion—$91.7 billion, compared to the consensus of $90.99 billion. The Medtech giant expects 2025 adjusted EPS of $10.75–$10.95 versus a consensus of $10.59.
The company expects to accelerate the launch of newly launched products in the MedTech segment, with the full benefit of the Shockwave acquisition through May. JNJ sees normalized procedure volume and seasonality.
Earlier this month, Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc. (NASDAQ:ITCI) for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Price Action: At last check on Wednesday, JNJ stock was down 1.69% to $145.65 during the premarket session.
Read Next:
Image By Sundry Photography Via Shutterstock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。